Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

BMS 433796

Catalog No: tcsc0661

Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Specifications

CAS No:
935525-13-6

Formula:
$C_{19}H_{16}F_2N_4O_4$

Pathway:
Stem Cell/Wnt;Neuronal Signaling

Target:
γ-secretase;γ-secretase

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Observed Molecular Weight:
402.35

Product Description

BMS 433796 is a **γ-secretase** inhibitor with **Aβ** lowering activity in a transgenic mouse model of Alzheimer\'s disease.

IC50 & Target: γ-secretase[1]

In Vitro:

BMS-433796 cause a concentration-dependent decrease in [^{3}H]IN973 binding, with IC_{50} value of 1.2 nM, very similar to the IC_{50} values for inhibition of Aβ40 in human embryonic kidney cells overexpressing the Swedish mutation of APP of 0.8 nM, respectively, and for inhibition of Aβ42 of 0.4 nM, respectively[2].

In Vivo: BMS 433796 is characterized in pharmacokinetic studies in male Sprague-Dawley rats. Following a 10-min intravenous infusion at 2.3 μmol/kg in PEG-400, the total body clearance of 40 is 5.2±0.82 mL/min/kg (means±SEM; n=3), indicating low clearance. The apparent terminal elimination half-life is 4.6±0.48 h. Oral administration of a PEG-400 suspension at 35 μmol/kg shows an oral bioavailability of 31% with prolonged absorption. BMS 433796 has satisfactory metabolic stability in human liver microsomal preparations and is not an inhibitor of human CYPs (IC_{50}>100 μM)[1]. Brain Aβ40 is reduced as a result of administering BMS-433796 in a dose-dependent manner, with ED_{50} value of 2.4 mg/kg, respectively[2].